2147 related articles for article (PubMed ID: 20566977)
1. Completion axillary lymph node dissection not required for regional control in patients with breast cancer who have micrometastases in a sentinel node.
Yegiyants S; Romero LM; Haigh PI; DiFronzo LA
Arch Surg; 2010 Jun; 145(6):564-9. PubMed ID: 20566977
[TBL] [Abstract][Full Text] [Related]
2. Prognostic implications of isolated tumor cells and micrometastases in sentinel nodes of patients with invasive breast cancer: 10-year analysis of patients enrolled in the prospective East Carolina University/Anne Arundel Medical Center Sentinel Node Multicenter Study.
Reed J; Rosman M; Verbanac KM; Mannie A; Cheng Z; Tafra L
J Am Coll Surg; 2009 Mar; 208(3):333-40. PubMed ID: 19317993
[TBL] [Abstract][Full Text] [Related]
3. Axillary lymph node dissection for sentinel lymph node micrometastases may be safely omitted in early-stage breast cancer patients: long-term outcomes of a prospective study.
Langer I; Guller U; Viehl CT; Moch H; Wight E; Harder F; Oertli D; Zuber M
Ann Surg Oncol; 2009 Dec; 16(12):3366-74. PubMed ID: 19760047
[TBL] [Abstract][Full Text] [Related]
4. Erratum to: Axillary recurrence rate following negative sentinel node biopsy for invasive breast cancer: long-term follow-up.
Kiluk JV; Ly QP; Santillan AA; Meade T; Ramos D; Reintgen DS; Dessureault S; Davis M; Shamehdi C; Cox CE
Ann Surg Oncol; 2010 Feb; 17(2):552-7. PubMed ID: 19957043
[TBL] [Abstract][Full Text] [Related]
5. Avoidance of axillary lymph node dissection in selected patients with node-positive breast cancer.
Noguchi M
Eur J Surg Oncol; 2008 Feb; 34(2):129-34. PubMed ID: 17498911
[TBL] [Abstract][Full Text] [Related]
6. Recurrence rates in breast cancer patients with false-negative intraoperative evaluation of sentinel lymph nodes.
Taras AR; Hendrickson NA; Lowe KA; Atwood M; Beatty JD
Am J Surg; 2010 May; 199(5):625-8. PubMed ID: 20466106
[TBL] [Abstract][Full Text] [Related]
7. The effect of sentinel node tumor burden on non-sentinel node status and recurrence rates in breast cancer.
Fan YG; Tan YY; Wu CT; Treseler P; Lu Y; Chan CW; Hwang S; Ewing C; Esserman L; Morita E; Leong SP
Ann Surg Oncol; 2005 Sep; 12(9):705-11. PubMed ID: 16079953
[TBL] [Abstract][Full Text] [Related]
8. Axillary recurrences after negative sentinel lymph node biopsy under local anaesthesia for breast cancer: a follow-up study after 5 years.
Groetelaers RP; van Berlo CL; Nijhuis PH; Schapers RF; Gerritsen HA
Eur J Surg Oncol; 2009 Feb; 35(2):159-63. PubMed ID: 18789841
[TBL] [Abstract][Full Text] [Related]
9. Axillary node staging for microinvasive breast cancer: is it justified?
Lyons JM; Stempel M; Van Zee KJ; Cody HS
Ann Surg Oncol; 2012 Oct; 19(11):3416-21. PubMed ID: 22576061
[TBL] [Abstract][Full Text] [Related]
10. Low locoregional failure rates in selected breast cancer patients with tumor-positive sentinel lymph nodes who do not undergo completion axillary dissection.
Hwang RF; Gonzalez-Angulo AM; Yi M; Buchholz TA; Meric-Bernstam F; Kuerer HM; Babiera GV; Tereffe W; Liu DD; Hunt KK
Cancer; 2007 Aug; 110(4):723-30. PubMed ID: 17587208
[TBL] [Abstract][Full Text] [Related]
11. Influence of frozen-section analysis of sentinel lymph node and lumpectomy margin status on reoperation rates in patients undergoing breast-conservation therapy.
McLaughlin SA; Ochoa-Frongia LM; Patil SM; Cody HS; Sclafani LM
J Am Coll Surg; 2008 Jan; 206(1):76-82. PubMed ID: 18155571
[TBL] [Abstract][Full Text] [Related]
12. Axillary recurrence in women with a negative sentinel lymph node and no axillary dissection in breast cancer.
Palesty JA; Foster JM; Hurd TC; Watroba N; Rezaishiraz H; Edge SB
J Surg Oncol; 2006 Feb; 93(2):129-32. PubMed ID: 16425295
[TBL] [Abstract][Full Text] [Related]
13. Sentinel lymph node biopsy is associated with improved survival compared to level I & II axillary lymph node dissection in node negative breast cancer patients.
Langer I; Guller U; Hsu-Schmitz SF; Ladewig A; Viehl CT; Moch H; Wight E; Harder F; Oertli D; Zuber M
Eur J Surg Oncol; 2009 Aug; 35(8):805-13. PubMed ID: 19046846
[TBL] [Abstract][Full Text] [Related]
14. Comparison of sentinel lymph node biopsy alone and completion axillary lymph node dissection for node-positive breast cancer.
Bilimoria KY; Bentrem DJ; Hansen NM; Bethke KP; Rademaker AW; Ko CY; Winchester DP; Winchester DJ
J Clin Oncol; 2009 Jun; 27(18):2946-53. PubMed ID: 19364968
[TBL] [Abstract][Full Text] [Related]
15. Omitting axillary lymph node dissection in sentinel node negative breast cancer patients is safe: a long term follow-up analysis.
Torrenga H; Fabry H; van der Sijp JR; van Diest PJ; Pijpers R; Meijer S
J Surg Oncol; 2004 Oct; 88(1):4-7; discussion 7-8. PubMed ID: 15384064
[TBL] [Abstract][Full Text] [Related]
16. Radiation field design and regional control in sentinel lymph node-positive breast cancer patients with omission of axillary dissection.
Setton J; Cody H; Tan L; Morrow M; Hudis C; Catalano J; McCormick B; Powell S; Ho A
Cancer; 2012 Apr; 118(8):1994-2003. PubMed ID: 21882186
[TBL] [Abstract][Full Text] [Related]
17. A Randomized clinical trial on sentinel lymph node biopsy versus axillary lymph node dissection in breast cancer: results of the Sentinella/GIVOM trial.
Zavagno G; De Salvo GL; Scalco G; Bozza F; Barutta L; Del Bianco P; Renier M; Racano C; Carraro P; Nitti D;
Ann Surg; 2008 Feb; 247(2):207-13. PubMed ID: 18216523
[TBL] [Abstract][Full Text] [Related]
18. Obesity is a risk factor for developing postoperative lymphedema in breast cancer patients.
Helyer LK; Varnic M; Le LW; Leong W; McCready D
Breast J; 2010; 16(1):48-54. PubMed ID: 19889169
[TBL] [Abstract][Full Text] [Related]
19. Axillary regional recurrence after sentinel lymph node biopsy for breast cancer.
Rosing DK; Dauphine CE; Vargas MP; Gonzalez K; Burla M; Kaufmann P; Vargas HI
Am Surg; 2006 Oct; 72(10):939-42. PubMed ID: 17058740
[TBL] [Abstract][Full Text] [Related]
20. Axillary recurrence rate after tumour negative and micrometastatic positive sentinel node procedures in breast cancer patients, a population based multicenter study.
Bulte CS; van der Heiden-van der Loo M; Hennipman A
Eur J Surg Oncol; 2009 Jan; 35(1):25-31. PubMed ID: 18640809
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
